华润医药(03320.HK)发布2025年中期业绩，该集团取得收益人民币1318.67亿元(单位下同)，同比增加 2.54%;公司权益股东应占溢利20.77亿元，同比减少20.25%;每股盈利0.33元，拟派发中期股息每股0.072 元。 本文源自：金融界AI电报 ...

Core Points - The company has completed the registration capital change and the amendment of its Articles of Association following the approval of a share repurchase plan [2][3] - The registered capital of the company is now RMB 323,215.0988 million, reflecting an increase from the previous amount [2] - The company has obtained a new business license from the Jilin Provincial Market Supervision Administration [2] Summary by Sections - **Share Repurchase Plan**: The board of directors approved a share repurchase plan to buy back shares for the purpose of cancellation and reduction of registered capital [2] - **Business License and Registration Details**: The company has updated its business license, with the new registered capital and other relevant details [2] - **Amendments to Articles of Association**: The amendments include changes to the registered capital and total number of shares, while other provisions remain unchanged [2]